Annual report pursuant to Section 13 and 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:    
Research and development $ 7,839 $ 8,765
General and administrative 6,162 4,881
Total operating expenses 14,001 13,646
Operating loss (14,001) (13,646)
Other income:    
Other income, net 353 82
Total other income, net 353 82
Loss before income tax expense (13,648) (13,564)
Income tax expense (28) (28)
Net loss (13,676) (13,592)
Other comprehensive loss    
Unrealized loss on marketable securities (23) (49)
Net loss and comprehensive loss $ (13,699) $ (13,641)
Basic and diluted net loss per share (in dollars per share) $ (0.52) $ (0.65)
Weighted average shares outstanding – basic and diluted (in shares) 26,443,067 20,773,399